Apyx Medical Corporation (NASDAQ:APYX), the maker of Renuvion®, a proprietary helium plasma and radiofrequency platform technology, today released its financial results for the fourth quarter and full year ended December 31, 2024.
For the fourth quarter of 2024, Apyx reported a net loss attributable to stockholders of $4.6 million, or $0.12 per share, a significant improvement from the $9.6 million loss, or $0.28 per share, recorded in the same period of 2023.
Total revenue for the quarter dipped slightly to $14.2 million, down from $14.7 million in the prior year.
The Advanced Energy segment, a key driver of the company’s sales, remained steady at $12.1 million, while the OEM (Original Equipment Manufacturer) segment saw a decline to $2.1 million from $2.5 million in Q4 2023.
For the full year, Apyx’s total revenue fell 8% to $48.1 million, compared to $52.3 million in 2023.
The Advanced Energy segment experienced an 11% drop, with sales decreasing to $38.6 million from $43.4 million the previous year.
However, the OEM segment bucked the trend, posting a 6% increase to $9.5 million, up from $9 million in 2023.
The company’s full-year net loss widened to $23.5 million, or $0.66 per share, compared to $18.7 million, or $0.54 per share, in 2023.
Looking ahead, Apyx refined its financial guidance for 2025, projecting total revenue in the range of $47.6 million to $49 million.
This outlook suggests a potential stabilization or slight growth compared to the $48.1 million recorded in 2024, reflecting cautious optimism for the year ahead.